WO2005082391A1 - ヒトβ3アドレナリン受容体アゴニスト剤 - Google Patents
ヒトβ3アドレナリン受容体アゴニスト剤 Download PDFInfo
- Publication number
- WO2005082391A1 WO2005082391A1 PCT/JP2005/003284 JP2005003284W WO2005082391A1 WO 2005082391 A1 WO2005082391 A1 WO 2005082391A1 JP 2005003284 W JP2005003284 W JP 2005003284W WO 2005082391 A1 WO2005082391 A1 WO 2005082391A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- human
- adrenergic receptor
- receptor agonist
- obesity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
Definitions
- the present invention provides a human ⁇ 3 adrenergic receptor agonist, and prevention of lifestyle-related diseases such as obesity, obesity, diabetes, hyperlipidemia, hypertension, and gout, characterized by containing the same. And ⁇ or an improving agent.
- Adrenaline receptors are receptors that bind to catecholamine agonists such as adrenergic and noradrenaline released by sympathetic nervous system, and are classified into two types, OC receptors and ⁇ receptors, depending on their sensitivity to catecholamine agonists. That is, the OC adrenergic receptor is sensitive in the order of noradrenaline ⁇ adrenaline> dopamine> isoproterenol, and the j8 adrenergic receptor is sensitive in the order of isoproterenol> adrenaline ⁇ noradrenaline> donomin.
- ⁇ -adrenergic receptors include ⁇ , ⁇ 2, and ⁇ 3 receptors, and the presence of ⁇ 4 receptors has recently been suggested.
- the effects of agonists (agonists) on each receptor include ⁇ 1 -adrenergic receptor agonists, which increase heart rate, ⁇ 2 -adrenergic receptor agonists, which relax bronchial smooth muscle, and ⁇ 3 -adrenergic receptor agonists, which produce heat. It is known that there is an activity of producing lipstick and an action of promoting lipolysis. For this reason, ⁇ 3 adrenergic receptor agonists are effective in preventing and / or improving lifestyle-related diseases such as obesity.
- Non-Patent Document 1 Recently, several compounds have been known as selective human j83 adrenergic receptor agonists (see Non-Patent Document 1), and their effects as antiobesity drugs or antidiabetic drugs in clinical trials. Has been confirmed. However, human ⁇ 3 adrenergic receptor agonists derived from natural materials with dietary experience are still unknown.
- Kinren power is a plant belonging to the genus Trollius, which is a member of the family Ranunculaceae (Trollius). It is effective and is used as a tea flower (see Non-Patent Document 3).
- Sanjak is a plant belonging to the genus Dioscorea (Dioscorea), and its succulent root has been known to have tonic and nourishing effects since ancient times. (See Non-Patent Document 4).
- Sanrillo is a plant belonging to the genus Sparganium of the family Papaveraceae, and is roughly divided into three ridges and three ridges.
- the rhizome is called the root of Sparganium stenophyllum Maxim., S. simplex Huds., And S. minimum Hill., A closely related species in China, especially in the Tohoku region. In Zhejiang province, the rhizome of S. longifolium Turcz.
- the thorns are originally rhizomes of Scirpus yagara Ohwi, a member of the family Cypemceae. These are used as one of the merits and lactation drugs. (See Non-Patent Document 4).
- Kinkaran is a plant belonging to the genus Tinospora in the family Scarabaeidae.
- the water or ethanol extract of the tuberous root has a thymic atrophy effect, an anti-adrenal corticosteroid-like effect and an inhibitory effect on Mycobacterium tuberculosis by oral administration to egrets and mice.
- Chinese practice It has antipyretic and antiphlogistic analgesic effects on fever caused by flu, acute tonsillitis, pneumonia, biliary tract infections, and suppurative cutaneous infections, but is reported to have few side effects.
- Quincalane is used as an antipyretic and antidote for acute, chronic tonsillitis, acute sore throat, stomatitis, parotitis, mastitis, appendicitis, acute chronic enteritis, gastritis, and foods.
- it is used as a veterinary drug for syphilia, swelling, and anthrax (see Non-Patent Document 4).
- Non-patent document 1 Yasuhito Takakura, Toshihide Yoshida, Nippon Pharmacological Journal, 118, 315-320, 2001
- Non-patent document 2 C. Weyer, et al., Diabetes & Metabolism, 25, 11-21, 1999
- Non-Patent Document 3 Mitsuru Hotta (Editor's Representative), World Useful Plant Encyclopedia, Heibonsha
- Non-Patent Document 4 Hiroshi Mitsuhashi, Primary Color Makino Kazoku Herbal Herbal Encyclopedia, Hokuryukan
- the present invention provides a human ⁇ 3 adrenergic receptor agonist, which is derived from a safe natural material having a dietary experience, and an obesity, obesity, diabetes, high fat containing the same.
- An object of the present invention is to provide a prophylactic and / or ameliorating agent for lifestyle-related diseases such as hematosis, hypertension, and gout.
- the present inventors have conducted intensive studies in order to solve the above-described problems, and as a result, extracted Kinren force, liquorum, liquorice and Quincalane with a solvent, particularly a solvent containing a water-soluble organic solvent.
- the present inventors have found that the extracts obtained, such as the extract of cinren, the extract of mung bean, the extract of liquorice, the extract of liquorice and the extract of quinkalan have a human ⁇ 3 adrenergic receptor agonist action, and have completed the present invention.
- the present invention provides a human 133 adrenergic receptor ago comprising at least one selected from the group consisting of a nasturtium extract, a juniper extract, a sanryo extract, and a kumquat extract extract as an active ingredient. -Regarding strike agents. Further, the present invention relates to a preventive and / or ameliorating agent for lifestyle-related diseases, which comprises the above-mentioned human
- the present invention relates to a method for preventing and / or ameliorating lifestyle-related diseases by administering the human
- the human j83 adrenergic receptor agonist of the present invention has at least one active ingredient selected from the group consisting of a kumren extract, a juniper extract, a sanryo extract and a kumkarane extract.
- the human j83 adrenergic receptor agonist agent of the present invention may be the extract itself, or the extract may be supplemented with known carriers, auxiliaries, food and drink materials, other pharmaceutically acceptable formulation materials, and the like.
- a composition may be used.
- the human ⁇ 3 adrenergic receptor agonist is derived from a dietary natural material.
- the Kinren force (gold lotus flower) used in the present invention is a flower of a plant belonging to the genus Trollius of the family Ranunculaceae.
- any varieties of the genus Aurelia may be used, but Trollius chinensis Bge.
- the juniper (yamayaku) used in the present invention is also called as zinenjiyo, and is a succulent root of a plant of the genus Dioscorea, which is dried after washing with water and removing the skin.
- Sanryo used in the present invention is a rhizome of a plant belonging to the genus Sparganium of the family Papaveraceae.
- Sparganium stenophyllum Maxim. Ezomitari S. simplex Huds., S. minimum Hill., S. longifolium Turcz.
- Kinkaran used in the present invention is a tuberous root of a plant belonging to the genus Tinospora (Tinospora). In the present invention, any variety of the genus Tinospora can be used. 7) ⁇ TinosDora capillipes Gagnep.
- the kumren power, the cinnamon extract, the sanryou extract, and the quinkalan extract used in the present invention can also be obtained by the solvent extraction and the like, as well as the kinlen power, cinnamon, sanryou and kumcaran powers.
- the extract can be used in the present invention as an extract, or as a crude extract or a semi-purified extract, as long as it does not contain impurities unsuitable for beverages and pharmaceuticals.
- a flower of a kinren power for example, a flower of a kinren power, a succulent root of a liquorice, a rhizome of a liquorice, or a tuberous root of a quinkalan may be used in its original form, or crushed or powdered, on a weight basis.
- the extract is usually immersed in 120-fold volume, preferably 3-10-fold volume, of the following extraction solvent, and extracted by stirring, Z or standing, and an extract can be obtained by filtration or centrifugation.
- the solvent can be removed from the obtained extract by concentration and Z or concentration to dryness to obtain the extract.
- the extraction solvent a solvent containing a water-soluble organic solvent is preferable.
- the solvent containing the water-soluble organic solvent is preferably a solvent composed of only the water-soluble organic solvent or a mixture of the water-soluble organic solvent and water.
- water-soluble organic solvent lower alcohols having 13 to 13 carbon atoms (eg, methanol, ethanol, 1-propanol and 2-propanol) are more preferable, and ethanol is particularly preferable in view of the safety of the residual solvent. .
- the concentration of the water-soluble organic solvent is preferably 10% by volume or more, more preferably 50% by volume or more, and particularly preferably 90% by volume or more.
- an aqueous solution containing 10% by volume or more of a water-soluble organic solvent is preferable as an extraction solvent, and an aqueous solution containing 50% by volume or more of a water-soluble organic solvent is more preferable.
- An aqueous solution containing at least volume% is particularly preferred.
- the upper limit of the concentration of the water-soluble organic solvent is not particularly limited, and is preferably 100% by volume or less.
- the extraction temperature is not particularly limited, and the extraction can be suitably performed usually at 20 to 100 ° C, preferably at 1 to 80 ° C, and more preferably at 20 to 60 ° C.
- the extraction time is not particularly limited, and the extraction can be suitably carried out usually for 0.1 hour to 1 month, preferably for 0.5 hour to 7 days.
- the method for evaluating the action of human 133 adrenergic receptor agonist is not particularly limited. However, for example, it can be evaluated by using cells expressing the human j83 adrenergic receptor. That is, in an in vitro experimental system, human ⁇ 3 adrenergic receptor is stably expressed in animal cells such as CHO cells (cultured cells derived from Chinese gno and muscular ovaries), and the extract is then added to the cells. Can be evaluated by measuring the increase in intracellular cyclic AMP concentration (AA Konkar, et al., J. Pharmacol. Exp. Ther., 291, 875—883, 1999; T. Kiso, et al. al., Biol. Pharm.
- CRE-LUCi is a reporter gene in which a luciferase (LUC) gene is linked to a cyclic AMP response element (CRE), and luciferase is expressed by an increase in intracellular cyclic AMP concentration.
- the preventive and / or ameliorating agent for lifestyle-related diseases of the present invention contains the above-mentioned human ⁇ 3-adrenergic receptor agonist.
- the human 883 adrenergic receptor agonist agent of the present invention has an activity of activating thermogenesis and a lipolytic effect, and is used for lifestyle such as obesity, obesity, diabetes, hyperlipidemia, hypertension, and gout. It can be used as an agent for preventing and / or improving disease.
- the human ⁇ 3 adrenergic receptor agonist of the present invention has a high body fat percentage, hyperglycemia, hyperinsulinemia, hypercholesterolemia, hypertriglyceridemia, hypertension and hyperuricemia. It can be used as a preventive and / or ameliorating agent for at least one symptom selected from the group.
- Obesity and obesity referred to herein conform to the obesity diagnostic criteria of the Japan Obesity Society. That is, obesity is defined as having a BMI (Body Mass Index: body weight (kg) Z height (m) 2 ) of 25 or more. Obesity is obesity and impaired health due to obesity or visceral fat-type fertilization. Is defined as full. Visceral fat-type obesity is determined when the waist (diameter of the navel) is 85 cm or more in men, 90 cm or more in women, or the visceral fat area by abdominal CT examination is 100 cm 2 or more.
- BMI Body Mass Index: body weight (kg) Z height (m) 2 ) of 25 or more.
- Obesity is obesity and impaired health due to obesity or visceral fat-type fertilization. Is defined as full. Visceral fat-type obesity is determined when the waist (diameter of the navel) is 85 cm or more in men, 90 cm or more in women, or the visceral fat area by abdominal CT examination is 100 cm 2 or
- Health disorders due to obesity include: 1) type 2 diabetes * impaired glucose tolerance, 2) abnormal lipid metabolism, 3) hypertension, 4) hyperuricemia / gout, 5) coronary artery disease (myocardial infarction / angina pectoris) , 6) cerebral infarction (cerebral thrombosis ⁇ transient ischemic attack), 7) sleep apnea syndrome ⁇ Pickwick syndrome, 8) fatty liver, 9) orthopedic diseases (osteoarthritis ⁇ lumbar spondylopathy), 10) Menstrual disorder, at least one selected from the group consisting of:
- the above-mentioned obesity also includes a state of a high body fat rate in which the body fat rate is 25% or more in men and 30% or more in women.
- the type 2 diabetes mellitus' impaired glucose tolerance also includes, for example, conditions such as hyperglycemia and hyperinsulinemia.
- Abnormal lipid metabolism includes, for example, hypercholesterolemia, hypertriglyceridemia, hyper-LDL-cholesterolemia, and low-HDL-cholesterolemia.
- Prevention and / or improvement of lifestyle-related diseases such as obesity, obesity, diabetes, hyperlipidemia, hypertension, and gout characterized by containing the human ⁇ 3 adrenergic receptor agonist agent of the present invention.
- the preventive and / or ameliorating agent for at least one symptom selected from the group consisting of hypertension and hyperuricemia (hereinafter referred to as the preventive / ameliorating agent of the present invention) can be used for eating and drinking and for medicine. The form is not limited.
- foods and drinks such as functional health foods (specified health foods and nutritional foods), health foods, dietary supplements, and functional foods, or over-the-counter drugs and over-the-counter drugs (over-the- counter drug: OTC) How readily be utilized as such available pharmaceutical or quasi drug.
- the prophylactic / ameliorating agent of the present invention when used as a food or drink, it can be taken directly as it is, and it can be used as a capsule, tablet, granule, etc. using known additives such as carriers and auxiliaries. It can be ingested in a form that is easy to do.
- the content of the preventive / improving agent of the present invention in these molding agents is preferably 0.1 to 100% by weight, more preferably 2 to 95% by weight, and still more preferably 10 to 90% by weight.
- the preventive / improving agent of the present invention is mixed with a food or drink material to prepare a chewing gum or chocolate.
- the amount of the extract is preferably 0.01 to 100 mgZkg, more preferably 0.1 to 100 mgZkg per adult per day in terms of the extract.
- its dosage form is not particularly limited, and examples include capsules, tablets, granules, injections, suppositories, and patches.
- other pharmaceutically acceptable drug substances such as excipients, disintegrants, lubricants, binders, antioxidants, coloring agents, anti-agglomeration agents, absorption promoters, dissolution aids It can be prepared by appropriately adding agents, stabilizers and the like.
- the dose of these preparations is preferably 0.01 to 100 mgZkg body weight, more preferably 0.1 to 100 mgZkg body weight per adult per day in terms of the extract, divided into one or several doses.
- additives When used as a quasi-drug, other additives may be added as necessary, for example, ointments, liniments, aerosols, creams, stones, facial cleansers, body wash, lotion , Mouthwash, bath agent, etc., and can be used topically.
- the method of the present invention for preventing and / or ameliorating a lifestyle-related disease comprises administering the above-mentioned human ⁇ 3 adrenergic receptor agonist.
- the human j83 adrenergic receptor agonist can be administered in the form and dosage used in the above-mentioned foods and drinks, pharmaceuticals, quasi-drugs and the like.
- a human ⁇ 3 -adrenoceptor receptor agonist derived from a safe natural material having experience in eating.
- the composition containing it is useful as an agent for preventing and / or improving lifestyle-related diseases such as obesity, obesity, diabetes mellitus, hyperlipidemia, hypertension, and gout.
- Kinren Riki no Hana (Shinwa Bussan Co., Ltd.) is finely cut, crushed by a crusher, and 2 g of the crushed product is extracted with 10 ml of 99.5% by volume ethanol / Z water (room temperature (23-24 ° C) , And left in a dark place for 3 days), followed by filtration and concentration to dryness, to obtain 87.7 mg of a kinren power extract.
- Kinkaran tuberous root (Shinwa Bussan Co., Ltd.) is cut into fine pieces, crushed with a crusher, and 2 g of the crushed product is extracted with 99.5% by volume ethanol Z water (10 ml) (room temperature (23-24 ° C), The mixture was allowed to stand in a dark place for 3 days), filtered, and concentrated to dryness to obtain 69.3 mg of a kumcaran extract.
- CHO- K1 cells Choinese 'Bruno, cultured cells derived from Muster ovaries
- the expression plasmid for human beta 3 adrenergic phosphate receptor gene, lipoic Hue transfected ⁇ Min T M 2000 is a gene transfer reagent (Invitrogen)
- the cells were transfected to obtain cells expressing human j83 adrenergic receptor (hereinafter referred to as ⁇ 3ZCHO cells).
- Day 1 of experiment j8 3ZCHO cells were inoculated into a 96-well culture plate at 3 ⁇ 10 4 cells / well and cultured at 37 ° C. under 5% CO for about 24 hours.
- the medium contains 5% FBS ( ⁇
- HD medium containing fetal serum was used.
- the HD medium was Ham F-12 (SIGMA) 5.35 gZL, DMEM (GIBCO) 4.75 gZL, L-glutamine (Wako Pure Chemical Industries) 0. 59gZL, CaCl-2H0 (Wako Pure Chemical Industries, Ltd.) 0.044g / L, sodium bicarbonate (GIBCO)
- PCRE-luc is a reporter plasmid in which a luciferase (luc) gene is linked to a cyclic AMP response 'element (CRE).
- the medium was replaced with a medium containing the sample (the extract obtained in each of Examples 14 to 14), and the cells were cultured for 6 hours.
- the medium containing the above sample was prepared by dissolving each of the above extracts in dimethylsulfoxide (DMSO) and adding 1Z1000 volume to the medium to obtain the concentrations shown in Table 1.
- DMSO alone was used as an untreated control
- BRL37344 (TOCRIS), a selective j83 adrenergic receptor antagonist, was used as a positive control.
- Table 1 shows the measurement results of the extracts obtained in Examples 14 to 14.
- BRL37344 increases the intracellular cyclic AMP concentration via human ⁇ 3 adrenergic receptor and expresses luciferase. The effect of adrenergic receptor agonist was confirmed.
- the capsule was filled in a node capsule to prepare a hard capsule for eating and drinking containing a citrus extract.
- a human ⁇ 3 adrenergic receptor agonist from a safe natural material having a dietary experience.
- the composition containing it is useful as an agent for preventing and / or improving lifestyle-related diseases such as obesity, obesity, diabetes mellitus, hyperlipidemia, hypertension, and gout.
Landscapes
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006510501A JPWO2005082391A1 (ja) | 2004-03-01 | 2005-02-28 | ヒトβ3アドレナリン受容体アゴニスト剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004055866 | 2004-03-01 | ||
JP2004-055866 | 2004-03-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005082391A1 true WO2005082391A1 (ja) | 2005-09-09 |
Family
ID=34908882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/003284 WO2005082391A1 (ja) | 2004-03-01 | 2005-02-28 | ヒトβ3アドレナリン受容体アゴニスト剤 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPWO2005082391A1 (ja) |
TW (1) | TW200533366A (ja) |
WO (1) | WO2005082391A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007295833A (ja) * | 2006-04-28 | 2007-11-15 | Tokachiken Shiko Kiko | 長いも凍結乾燥粉末を含む生活習慣病予防食品 |
JP2009540002A (ja) * | 2006-06-14 | 2009-11-19 | 國立陽明大學 | 糖尿病性血管合併症の治療方法 |
CN102716347A (zh) * | 2012-06-29 | 2012-10-10 | 宋永心 | 一种治疗高血压病的藏药及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0549432A (ja) * | 1991-08-23 | 1993-03-02 | Takano Co Ltd | 食品添加剤 |
JP2002080323A (ja) * | 2000-08-22 | 2002-03-19 | L'oreal Sa | 組成物、特にサポゲニン及びキサンチンベースを含む化粧品組成物 |
JP2003095930A (ja) * | 2001-09-20 | 2003-04-03 | Kagome Co Ltd | 抗肥満剤 |
JP2005060366A (ja) * | 2003-07-29 | 2005-03-10 | Kao Corp | 脂肪分解促進剤 |
WO2005042508A1 (ja) * | 2003-11-04 | 2005-05-12 | Meiji Dairies Corporation | 植物由来β3アドレナリン受容体作動性物質およびその利用 |
-
2005
- 2005-02-28 JP JP2006510501A patent/JPWO2005082391A1/ja active Pending
- 2005-02-28 WO PCT/JP2005/003284 patent/WO2005082391A1/ja active Application Filing
- 2005-03-01 TW TW094106023A patent/TW200533366A/zh unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0549432A (ja) * | 1991-08-23 | 1993-03-02 | Takano Co Ltd | 食品添加剤 |
JP2002080323A (ja) * | 2000-08-22 | 2002-03-19 | L'oreal Sa | 組成物、特にサポゲニン及びキサンチンベースを含む化粧品組成物 |
JP2003095930A (ja) * | 2001-09-20 | 2003-04-03 | Kagome Co Ltd | 抗肥満剤 |
JP2005060366A (ja) * | 2003-07-29 | 2005-03-10 | Kao Corp | 脂肪分解促進剤 |
WO2005042508A1 (ja) * | 2003-11-04 | 2005-05-12 | Meiji Dairies Corporation | 植物由来β3アドレナリン受容体作動性物質およびその利用 |
Non-Patent Citations (7)
Title |
---|
"Genshoku Makino Wakan Yakuso Daizukan." * |
AKAMATSU K.: "Shintei Wakan'yaru.", ISHIYAKU PUB.INC. * |
COMT.REND., vol. 252, 1961, pages 1510 - 1511 * |
DATABASE CAPLUS [online] RAYMOND P.R. ET AL: "Isolation of a flavonol Glucoside, identified as isoqercitrin, from the leavels of nasturtium (Tropaelum majus)", accession no. STN Database accession no. (1961:76724) * |
KUPPUSAMY U.R. ET AL: "Potentiation of beta-adrenoceptor agonist-mediated lipolysis by quercetin and fisetin in isolated rat adipocytes.", BIOCHEMICAL PHARMACOLOGY., vol. 47, no. 3, 1994, pages 521 - 519, XP025552593, DOI: doi:10.1016/0006-2952(94)90184-8 * |
KWON C.S. ET AL: "Anti-obesity Effect of Dioscorea nopponica Makino with Lipase inhibitory Activity in Rodents.", BIOSCI.BIOTECHNOL.BIOCHEM., vol. 67, no. 7, 2003, pages 1451 - 1456 * |
SEKITANI K. ET AL: "Nagaimo ni yoru Shibo Saibo Bunka no Sokushin to Insulin Kanjusei no Josho.", JOURNAL OF TRADITIONAL MEDICINES., vol. 19, 2002, pages 55 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007295833A (ja) * | 2006-04-28 | 2007-11-15 | Tokachiken Shiko Kiko | 長いも凍結乾燥粉末を含む生活習慣病予防食品 |
JP2009540002A (ja) * | 2006-06-14 | 2009-11-19 | 國立陽明大學 | 糖尿病性血管合併症の治療方法 |
CN102716347A (zh) * | 2012-06-29 | 2012-10-10 | 宋永心 | 一种治疗高血压病的藏药及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
TW200533366A (en) | 2005-10-16 |
JPWO2005082391A1 (ja) | 2007-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6745250B2 (ja) | モリンガエキス | |
JP2022023067A (ja) | ハマナスの花抽出物を有効成分として含むil-6媒介性疾患の予防又は治療用薬学的組成物 | |
JP2021501119A (ja) | 丹参抽出物を含む内臓脂肪型肥満予防、改善又は治療組成物 | |
KR101965061B1 (ko) | 땅콩 새싹 추출물 또는 이의 분획물을 포함하는 대사성 질환의 예방 또는 치료용 조성물 | |
KR20190090362A (ko) | 디카페오일퀴닌산을 유효성분으로 함유하는 비만 개선 조성물 | |
KR20120010026A (ko) | 백미 추출물을 포함하는 관절염 예방 및 치료용 조성물 | |
JP2008163014A (ja) | 11βHSD1阻害剤及びその用途 | |
JP2008222656A (ja) | 肥満改善および予防用組成物ならびに健康食品 | |
US20160074338A1 (en) | Food composition for preventing obesity, pharmaceutical composition for treating obesity, and animal medicine for treating obesity, containing gingernone a | |
JPWO2003007974A1 (ja) | Tnf産生抑制作用を有する組成物及びtnf産生抑制剤 | |
JP2022534165A (ja) | ニコチンアミドモノヌクレオチド及びモグロシドを含む組成物とその使用法 | |
WO2005082391A1 (ja) | ヒトβ3アドレナリン受容体アゴニスト剤 | |
JP2006096666A (ja) | 選択的ヒトβ3アドレナリン受容体アゴニスト剤 | |
KR20110056278A (ko) | 인슐린 민감성 강화제 및 항당뇨병제로서의 식물 추출물 | |
JP2006213657A (ja) | ヒトβ3アドレナリン受容体アゴニスト剤 | |
JP4371431B2 (ja) | 抗アレルギー性組成物 | |
KR101552282B1 (ko) | 디하이드로진저론을 함유하는 비만 치료 또는 예방용 조성물 | |
KR101248378B1 (ko) | 관절염 치료 및 예방용 약학조성물 | |
KR100973037B1 (ko) | 사우치논 또는 사우치논을 함유하는 삼백초 추출물을포함하는 아토피성 피부질환의 경감 또는 치료용 조성물 | |
KR20160094313A (ko) | 모과 추출물 또는 이의 분획물을 유효성분으로 함유하는 항비만용 조성물 | |
JPWO2004045632A1 (ja) | ペルオキシソーム増殖剤応答性受容体リガンド剤 | |
KR20130046094A (ko) | 어저귀 추출물을 포함하는 염증성질환 예방 또는 치료용 의약 조성물 | |
KR101903150B1 (ko) | 퀴니자린을 유효성분으로 포함하는 비만 예방 또는 치료용 조성물 | |
KR101471048B1 (ko) | 희렴 추출물을 포함하는 항비만 조성물 | |
WO2014156462A1 (ja) | 白色脂肪細胞の褐色様脂肪細胞分化誘導剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006510501 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |